Considering the differences between Chinese and Western studies regarding the efficacy of immunotherapy, we think that BRAF‐mutant patients with acral subtype melanoma would have less sensitivity to immunotherapy because of the low levels of tumor infiltrating lymphocyte (TIL) in acral lentiginous melanoma16 and low mutational loads in BRAF‐mut melanoma.17 The gene discussed is BRAF; the disease is melanoma.